‘Clean Slate’ For Rebate Policy? US MedPAC Getting To Work
Executive Summary
That sound you hear is the staff of the US Medicare Payment Advisory Commission digging into new sources of data about the impact of rebates on the Part D outpatient drug benefit. Expect new policy ideas to follow – though not right away.
You may also be interested in...
Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
Roxadustat Rejection Has Lessons For Other Sponsors
A US FDA Advisory Committee’s overwhelming rejection of FibroGen/AstraZeneca’s oral anti-anemia agent is a big setback for the sponsor. But the committee’s reaction to novel strategies used to try to save the application has an important message for all drug developers about the limits of those approaches.